Full Press Release Details
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers.
IDYA
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Key Takeaway: IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Price reaction · baseline $25.19 (2024-12-13 close) · 2 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
+3.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma